Pfizer News News 25 November 2025 - 6 February 2026

NEW YORK, Dec. 28, 2025, 2:50 p.m. ET — U.S. stock market closed (Sunday). Pfizer Inc. (NYSE: PFE) heads into the final week of 2025 with its shares hovering in the mid-$20s — a level Wall Street has increasingly framed as a “show-me” zone for investors who want evidence that Pfizer can navigate the post-COVID comedown and looming patent expirations while rebuilding growth through oncology and obesity-focused deals. With U.S. exchanges closed for the weekend, the most actionable information for investors is where Pfizer last finished the regular session, what (limited) fresh weekend reading emerged over the past 24–48 hours,

Pfizer Inc. (NYSE: PFE) stock is trying to steady itself in late December after a volatile stretch driven by one big theme: the post-COVID hangover is still real, and 2026 is shaping up as another “rebuild” year—even as Pfizer spends aggressively to reload its pipeline. As of Thursday, Dec. 18, 2025, Pfizer shares traded around $25.04, down about 1.8% from the prior close, according to the latest available trade time in the market feed. What’s making Pfizer stock interesting right now isn’t a single headline—it’s the collision of several: Below is a detailed, publication-ready roundup of the most current news,

Pfizer (NYSE: PFE) finished Wednesday’s session lower and traded only modestly in the after-hours market—an indication that investors are still digesting the company’s newly issued 2026 outlook while weighing fresh pipeline headlines and looming U.S. policy risk around drug pricing. Below is a detailed look at where Pfizer stock stands after the bell on Dec. 17, 2025, what news moved the narrative today, where Wall Street’s forecasts are landing, and what to watch before the opening bell Thursday, Dec. 18, 2025. Pfizer stock after the bell: the numbers investors are watching Pfizer shares closed at $25.04 on Wednesday, down about

(SEO): Pfizer stock (NYSE: PFE) held firm after the bell on Dec. 12, 2025. Here’s the full roundup of today’s headlines, analyst targets, and what to watch before the next market session. Pfizer, Inc. (NYSE: PFE) wrapped up Friday’s session (December 12, 2025) with a modest gain, then traded narrowly higher in extended hours as investors weighed a dense mix of shareholder-return news (dividend), regulatory headlines tied to COVID vaccines, and fresh oncology trial results—plus at least one notable analyst price-target cut. One important calendar note upfront: December 13, 2025 is a Saturday, and U.S. stock markets are closed. So

Pfizer Inc. (NYSE: PFE) ended the Friday, December 12, 2025 session slightly higher—and moved only modestly in after-hours trading—after a busy day of headline-driven catalysts. Investors weighed a newly declared $0.43 quarterly dividend, fresh FDA-related reporting tied to COVID-19 vaccine labeling, and late-stage oncology data involving Pfizer’s breast-cancer drug Tukysa (tucatinib). Reuters+3StockAnalysis+3Pfizer+3 Below is a detailed, publication-ready breakdown of what happened after the bell on 12/12/2025 and what to know heading into the next U.S. market session (note: U.S. stock markets do not hold a regular session on Saturday, December 13, 2025). Pfizer stock after the bell: the numbers investors